Anixa Biosciences Inc ANIX

US Biotechnology
$2.78 β–² +0.00% (+$0.00)
⬆️ Above Yest. High
Open $2.85
Prev Close $2.78
Day Range $2.69 – $2.87
52W Range $2.32 – $5.46
Market Cap $96.64M
Beta 0.51
EPS (TTM) $-0.31

πŸ“‹ Company Profile

IndustryBiotechnology
CountryUS
ExchangeNASDAQ NMS - GLOBAL MARKET
CurrencyUSD
IPO Date1983-10-07
Shares Out.34,020,000
Websiteanixa.com/ β†—
Phone13026587581
Employees4
Revenue$0
Gross Profit$0
Net Income-$2.6M
Free Cash Flow-$7.4M
Total Assets$15.1M
Total Liabilities$1.9M
Equity$13.2M
About Anixa Biosciences Inc

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

Anixa Biosciences Inc is a publicly traded company under the ticker symbol ANIX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.

πŸ“Š Analyst Ratings

10 analysts (2026-09-01)

Strong Buy 2
Buy 7
Hold 1

πŸ“° Latest News for ANIX

πŸ‘₯ Related Stocks